Vor Biopharma Inc.
VOR- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001817229
In the last 90 days, Vor Biopharma Inc. insiders filed 0 open-market purchases and 1 sale; 102 institutions reported holding it in 13F filings for Q2 2026, worth $893.0M in total; no superinvestor holds it.
Q2 2022 vs. Q1 2022
How the institutions holding Vor Biopharma Inc. changed between Q1 2022 and Q2 2022.
All holders in Q2 2022All holders in Q1 2022
| Measure | Q1 2022 | Of which not filed for Q2 2022 | Q2 2022 | Change |
|---|---|---|---|---|
| Holders | 58 | 1 | 49 | −8 |
| Shares | 31.1M | 2.38K | 31.2M | +64.9K (+0.2%) |
| Value | $187.9M | $14.0K | $154.8M | −$33.1M (−17.6%) |
1 institution that held it in Q1 2022 haven't filed for Q2 2022 yet. Not filing isn't selling, so the changes leave them out.
New holders (10)
Institutions that held Vor Biopharma Inc. at the end of Q2 2022 but not at the end of Q1 2022.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Baker Bros. Advisors LP | 1,138,768 | $5.66M | 0.03% |
| Bridgeway Capital Management, LLC | 69,400 | $345.0K | 0.01% |
| Susquehanna International Group, LLP | 53,074 | $264.0K | 0.00% |
| Renaissance Technologies LLC | 17,300 | $86.0K | 0.00% |
| Delphia (USA) Inc. | 16,132 | $80.0K | 0.06% |
| Virtu Financial LLC | 12,252 | $61.0K | 0.01% |
| Nisa Investment Advisors, LLC | 3,900 | $19.0K | 0.00% |
| UBS Group AG | 865 | $4.00K | 0.00% |
| Eagle Bay Advisors LLC | 150 | $746 | 0.00% |
| Credit Suisse AG | 10 | $0 | 0.00% |
Sold out (18)
Institutions that held Vor Biopharma Inc. at the end of Q1 2022 and filed for Q2 2022 without it.
| Institution | Shares, Q1 2022 | Value, Q1 2022 |
|---|---|---|
| Ameriprise Financial Inc | 82,705 | $500.0K |
| Nuveen Asset Management, LLC | 55,296 | $422.0K |
| HRT Financial LP | 63,414 | $383.0K |
| Bank of New York Mellon Corp | 55,375 | $335.0K |
| Bank of Montreal | 32,184 | $283.0K |
| Ensign Peak Advisors, Inc | 40,426 | $244.0K |
| Rhumbline Advisers | 16,332 | $99.0K |
| Virtus ETF Advisers LLC | 12,572 | $76.0K |
| Deutsche Bank AG | 10,617 | $64.0K |
| American International Group, Inc. | 9,421 | $57.0K |
| California State Teachers Retirement System | 8,221 | $50.0K |
| Barclays PLC | 3,083 | $19.0K |
| STRS Ohio | 2,700 | $16.0K |
| Amalgamated Bank | 2,380 | $14.0K |
| Legal & General Group Plc | 1,553 | $9.00K |
| Ameritas Investment Partners, Inc. | 1,483 | $9.00K |
| Royal Bank of Canada | 1,166 | $7.00K |
| Federated Hermes, Inc. | 88 | $1.00K |
Not filed for Q2 2022 yet (1)
Institutions that held Vor Biopharma Inc. at the end of Q1 2022 and haven't filed a 13F for Q2 2022. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q1 2022 | Value, Q1 2022 |
|---|---|---|
| Amalgamated Financial Corp. | 2,380 | $14.0K |